Combined treatment with @entity2727 and XXXX for accelerated response in the elderly: an open trial.

@entity1 @entity2011 @entity308 @entity390 @entity2133 @entity4164 @entity837 @entity148 @entity2727
BACKGROUND: Accelerated antidepressant treatment response may be particularly beneficial for older @entity1 , yet there are few data to inform clinical practice. We evaluated the potential of @entity2727 to accelerate antidepressant response to @entity837 and the safety and tolerability of the combined treatment in @entity1 with @entity308 . METHOD: We studied 11 elderly outpatients aged 70 years and older who were diagnosed with DSM-IV major @entity308 in a 10-week, open-label, structured trial (July 2001-July 2002). @entity2727 was tapered and discontinued during weeks 9 and 10. Response was defined as a Hamilton Rating Scale for @entity308 (HAM-D) score of less than 10. The daily dose of @entity837 ranged between 20 and 40 mg, and the daily dose of @entity2727 ranged between 5 and 20 mg. RESULTS: Nine @entity1 completed the study. Six @entity1 met criteria for accelerated response (HAM-D score < 10 and Clinical Global Impressions-Improvement scale score of 1 or 2 by treatment day 14), and 2 more @entity1 responded by week 3. One @entity1 was a nonresponder. The mean (SD) @entity837 dose for all subjects was 27.5 (10.3) mg and the mean (SD) @entity2727 dose was 12.2 (4.9) mg. The observed side effects were mild to moderate in severity and included sedation, @entity390 , @entity148 , @entity2011 , @entity2133 , and @entity4164 . CONCLUSION: @entity2727 augmentation of @entity837 may be a safe and viable strategy for accelerating antidepressant response in elderly @entity308 @entity1 . The results of this open-label trial need to be confirmed in a placebo-controlled trial.
